Kidney disease in chronic myeloid leukemia patients
Part of Blood & lymphatic, Cancer, Kidney & urinary clinical trials.
This study looks at people who have chronic myeloid leukemia and later develop kidney disease. It aims to see how the leukemia may affect the kidneys, and it might help find better ways to manage kidney health in CML patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have chronic myeloid leukemia (CML), a type of blood cancer, confirmed by a biopsy.
- You must have had a blood test called a complete blood count (CBC).
- You must not have had kidney disease before being diagnosed with CML.
- You must not have diabetes.
- Your kidney problem must not be from other causes like kidney stones, polycystic kidney disease, or long-term kidney infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This follow-up study looks at people with chronic myeloid leukemia (CML) who have been in deep remission and may be able to stay off treatment. It checks how long remission lasts and how their leukemia tests behave over time.
This study looks at certain immune cells called macrophages in the bone marrow of people with chronic myelomonocytic leukemia (CMML). It aims to better understand the disease, which may help improve treatments in the future.
This research study examines blood cells from patients with chronic myelomonocytic leukemia (CMML), a rare blood cancer, to better understand how the disease develops and progresses. By studying your blood cells, researchers hope to learn more about what causes CMML and how to treat it better.
This trial looks at how gut bacteria affect the way chronic myeloid leukemia (CML) patients respond to tyrosine kinase inhibitor (TKI) medications. It may help doctors understand why some people have better outcomes than others.
This study looks at the health and treatment patterns of people with chronic myeloid leukemia in Kuwait to better understand their needs and improve care.
This study uses a very sensitive blood test (digital PCR) to look for specific genetic mutations (changes) in the BCR::ABL1 gene in people with CML. The goal is to understand why some treatments stop working, which can help doctors choose the next best medication for you.
Hear when a new Chronic Myeloid Leukemia in Remission trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.